Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianda PharmaceuticalsHKSE:00455 +0.98%27 PS Ratio is 0.63 as of Sep. 08, 2026, which is 34% below its 10-year median of 0.95. GuruFocus rates HKSE:00455 with a GF Score™ of 27/100 and a GF Value™ of HK$0.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Tianda Pharmaceuticals ranks better than 84.29% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Tianda Pharmaceuticals's share price is HK$0.103.
Tianda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.16. Hence, Tianda Pharmaceuticals's PS Ratio for today is 0.63.
The historical rank and industry rank for Tianda Pharmaceuticals's PS Ratio or its related term are showing as below:
HKSE:00455'
s PS Ratio Range Over the Past 10 Years
Min: 0.57 Med: 0.95 Max: 5.53
Current: 0.64
During the past 13 years, Tianda Pharmaceuticals's highest PS Ratio was 5.53. The lowest was 0.57. And the median was 0.95.
HKSE:00455's PS Ratio is ranked better than 84.29% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.38
vs HKSE:00455: 0.64
Tianda Pharmaceuticals Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Tianda Pharmaceuticals was -2.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -14.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -8.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.50% per year.
During the past 13 years, Tianda Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 62.40% per year. The lowest was -25.50% per year. And the median was 7.25% per year.
Tianda Pharmaceuticals (HKSE:00455) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianda Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Tianda Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Tianda Pharmaceuticals's Share Price of today is HK$0.103.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tianda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Tianda Pharmaceuticals (HKSE:00455) has a PS Ratio of 0.63 as of Sep. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tianda Pharmaceuticals and its competitors. This is 34% below median its historical median of 0.95. Over the past decade, Tianda Pharmaceuticals' PS Ratio has ranged from 0.57 to 5.53. According to the industry distribution chart, Tianda Pharmaceuticals ranks #150 out of 955 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Tianda Pharmaceuticals' PS Ratio too high?
Tianda Pharmaceuticals' current PS Ratio of 0.63 is 34% below median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 5.53. The Drug Manufacturers industry median PS Ratio is 2.38. Tianda Pharmaceuticals' value of 0.63 is 73.5% below this industry median. Based on the distribution chart, Tianda Pharmaceuticals ranks #150 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianda Pharmaceuticals has a GF Score™ of 27/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tianda Pharmaceuticals' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianda Pharmaceuticals ranks #150 out of 955 companies for PS Ratio. This places Tianda Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.38. Tianda Pharmaceuticals' value of 0.63 is 73.5% below this benchmark. Historically, Tianda Pharmaceuticals' own PS Ratio has ranged from 0.57 to 5.53 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 2.38, Tianda Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.38, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianda Pharmaceuticals's current PS Ratio of 0.63 is 73.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tianda Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianda Pharmaceuticals's current PS Ratio is 0.63, which is 34% below median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tianda Pharmaceuticals (HKSE:00455) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.10 — trading 20.8% below its estimated fair value. The current PS Ratio is 0.63, which is 34% below median its 10-year median of 0.95 and 73.5% below the Drug Manufacturers industry median of 2.38. Tianda Pharmaceuticals' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Tianda Pharmaceuticals (HKSE:00455), the current PS Ratio is 0.63 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?
Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued.
The current stock price of HK$0.10 is trading 20.8% below its estimated GF Value™ of HK$0.13.
GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKSE:00455:
PS Ratio: 0.63 (34% below median its 10-year median of 0.95)
GF Value™: HK$0.13 vs. price of HK$0.10 (20.8% below fair value)
Industry Position: 73.5% below the Drug Manufacturers median (#150 of 955)
No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
27GF Score
Get the complete analysis for HKSE:00455
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00455 has been successfully added to your 
